Hydrogen-rich saline attenuates chemotherapy-induced ovarian injury via regulation of oxidative stress
Meng X, Chen H, Wang G, Yu Y, Xie K. · Experimental and Therapeutic Medicine. 2015;10(6):2277-2282.
Study at a glance
Preclinical
Two hundred forty adult virgin female Sprague-Dawley rats; ovarian injury was induced with cisplatin 5 mg/kg intraperitoneally on days 1 and 7.
H₂-rich saline 10 mL/kg intraperitoneally once daily from day 1 through day 14. · Hydrogen was dissolved for four hours at 0.4 MPa. The solution was stored at 4°C in gas-tight aluminium bags, made weekly and measured with a needle H₂ sensor to remain above 0.6 mmol/L.
Daily H₂-rich saline for 14 days; outcomes were assessed on days 14, 28 and 42 after cisplatin exposure.
Compared with cisplatin injury alone, H₂-rich saline was associated with higher estradiol, lower FSH, better follicular/histological measures, higher SOD/catalase, lower MDA and higher Nrf2 across the reported follow-ups. FSH did not differ between healthy control and healthy control plus H₂-rich saline. Fertility, pregnancy and anticancer efficacy were not tested.
Large animal count but preclinical model only; numerous surrogate outcomes and time-point comparisons, no fertility or live-birth endpoint, and no assessment of whether H₂ changed cisplatin's antitumor effect. Chinese national/provincial grants funded the study. No explicit conflict declaration was identified; absence is not inferred.
What kind of evidence is this?
Preclinical
Randomized four-group controlled rat experiment
Women’s health
Other forms
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Two hundred forty adult virgin female Sprague-Dawley rats; ovarian injury was induced with cisplatin 5 mg/kg intraperitoneally on days 1 and 7.
240 rats randomized equally to control, control plus H₂-rich saline, cisplatin injury, or cisplatin injury plus H₂-rich saline, n=60 per group; outcome sampling used n=10 per group at days 14, 28 and 42.
Daily H₂-rich saline for 14 days; outcomes were assessed on days 14, 28 and 42 after cisplatin exposure.
H₂-rich saline 10 mL/kg intraperitoneally once daily from day 1 through day 14.
H₂ dissolved in physiological saline — H₂ only, not Brown's gas.
Hydrogen was dissolved for four hours at 0.4 MPa. The solution was stored at 4°C in gas-tight aluminium bags, made weekly and measured with a needle H₂ sensor to remain above 0.6 mmol/L.
Untreated control, control plus H₂-rich saline and cisplatin-injury plus normal-saline conditions.
Outcomes and reported result
Serum estradiol and FSH, follicle counts and ovarian histology, serum/ovarian SOD, catalase and MDA, and ovarian Nrf2 expression.
Compared with cisplatin injury alone, H₂-rich saline was associated with higher estradiol, lower FSH, better follicular/histological measures, higher SOD/catalase, lower MDA and higher Nrf2 across the reported follow-ups. FSH did not differ between healthy control and healthy control plus H₂-rich saline. Fertility, pregnancy and anticancer efficacy were not tested.
The complete free PMC article was checked for all four arms, allocation, H₂ preparation and concentration, dose and timing, serial outcomes, funding and control-arm null finding.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Large animal count but preclinical model only; numerous surrogate outcomes and time-point comparisons, no fertility or live-birth endpoint, and no assessment of whether H₂ changed cisplatin's antitumor effect. Chinese national/provincial grants funded the study. No explicit conflict declaration was identified; absence is not inferred.
Cisplatin-associated ovarian injury in young rats; it does not establish fertility preservation or safety in patients receiving chemotherapy.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 26668628 · DOI: 10.3892/etm.2015.2787
Free full article in PubMed Central.
Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.